Health ❯Healthcare ❯Pharmaceuticals ❯Clinical Trials

Pain Management

Vertex Halts VX-993 Acute Pain Program After Phase 2 Trial Failure

The biotech will shift focus to a Phase 3 study of Journavx in diabetic neuropathy following the failed VX-993 trial.

Vertex Pain Drug Fails to Outperform Placebo in Key Study, Raising Concerns